Study protocol on prevalence of non-exudative macular neovascularisation and its contribution to prediction of exudation in fellow eyes with unilateral exudative AMD (EYE-NEON).


Journal

Eye (London, England)
ISSN: 1476-5454
Titre abrégé: Eye (Lond)
Pays: England
ID NLM: 8703986

Informations de publication

Date de publication:
10 2023
Historique:
received: 26 10 2022
accepted: 15 02 2023
revised: 26 01 2023
medline: 25 9 2023
pubmed: 8 3 2023
entrez: 7 3 2023
Statut: ppublish

Résumé

Fellow eyes of patients with unilateral neovascular age-related macular degeneration (nAMD) are at risk of developing macular neovascularisation (MNV). These eyes may first develop subclinical non-exudative MNV (neMNV) before they leak to form exudative MNV (eMNV). The EYE NEON study is a 2-year study aimed at estimating the prevalence and incidence of neMNV and evaluating its role as a predictor for conversion to neovascular AMD. EYE NEON is a multicentre study that will run in retinal clinics across 25 National Health Service with the aim to recruit 800 patients with new onset nAMD in the first eye. The fellow-eye with no evidence of nAMD at baseline will be the study eye. All study eyes will have OCT and OCTA done at first and second year following first anti-VEGF treatment to the first eye (non-study eye), with new onset nAMD. We will estimate the prevalence and incidence of neMNV over 2 years, rate of conversion from neMNV to eMNV and numbers initiated on treatment for neovascular AMD in the study eye will be reported. Predictive models of conversion including neMNV with other demographic and imaging parameters will be developed. The study design with proposed target sample size is sufficient to evaluate the retinal imaging characteristics of the study eyes with and without neMNV and develop predictive models to inform risk of conversion to nAMD.

Identifiants

pubmed: 36882530
doi: 10.1038/s41433-023-02460-9
pii: 10.1038/s41433-023-02460-9
pmc: PMC10516882
doi:

Substances chimiques

Angiogenesis Inhibitors 0
Neon 4VB4Y46AHD
Vascular Endothelial Growth Factor A 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3004-3008

Investigateurs

Ben Burton (B)
Geeta Menon (G)
Manju Chandran (M)
Ian Pearce (I)
Savitha Madusudhan (S)
Anna Grabowska (A)
Faruque Ghanchi (F)
James Talks (J)
Richard Gale (R)
Martin Mckibbin (M)
Ajay Kotagiri (A)
Niro Narendran (N)
Afsar Jafree (A)
Saad Younis (S)
Claire Bailey (C)
Priya Prakash (P)
Christiana Dinah (C)
Nitin Gupta (N)
Louise Downey (L)
Andrew Lotery (A)
Paritosh Shah (P)
Romi Chhabra (R)
Narendra Dhingra (N)
Indra Dias (I)
Mary Freeman (M)
Daren Hanumanthudu (D)
Asma Burale (A)
Radha Ramakrishnan (R)

Informations de copyright

© 2023. The Author(s).

Références

Am J Ophthalmol. 2017 Oct;182:45-55
pubmed: 28734811
JAMA Ophthalmol. 2021 May 01;139(5):542-547
pubmed: 33734306
Ophthalmol Retina. 2022 Jun;6(6):484-494
pubmed: 35121216
Retina. 2015 Nov;35(11):2204-11
pubmed: 26469533
Curr Opin Ophthalmol. 2013 May;24(3):190-6
pubmed: 23492430
Arch Ophthalmol. 1997 Jun;115(6):741-7
pubmed: 9194725
Ophthalmology. 2018 Feb;125(2):255-266
pubmed: 28964581
Ophthalmology. 2020 May;127(5):637-647
pubmed: 31899036
Oncotarget. 2017 Dec 12;9(8):7812-7821
pubmed: 29487693
Ophthalmol Retina. 2019 Mar;3(3):211-219
pubmed: 31014697
Arch Ophthalmol. 2007 Oct;125(10):1323-30
pubmed: 17923538
Ophthalmology. 2016 Jun;123(6):1309-19
pubmed: 26876696
Invest Ophthalmol Vis Sci. 2013 Oct 21;54(10):6886-92
pubmed: 24084095
Arch Ophthalmol. 1993 Sep;111(9):1189-99
pubmed: 7689826
Prog Retin Eye Res. 2018 Mar;63:132-146
pubmed: 29197628
Arch Ophthalmol. 2003 Apr;121(4):519-26
pubmed: 12695249
Indian J Ophthalmol. 2018 Dec;66(12):1796-1801
pubmed: 30451181
PLoS One. 2019 Jun 4;14(6):e0217805
pubmed: 31163067
Am J Ophthalmol. 2022 Apr;236:271-280
pubmed: 34699741
Ophthalmology. 2020 Jul;127(7):931-947
pubmed: 32247535
Invest Ophthalmol Vis Sci. 2017 Jul 1;58(9):3488-3495
pubmed: 28702676
JAMA Ophthalmol. 2019 Jul 1;137(7):738-744
pubmed: 31021381

Auteurs

Sridevi Thottarath (S)

NIHR Moorfields Clinical Research Facility and Biomedical Research Centre, Moorfields Eye Hospital, London, UK.

Shruti Chandra (S)

NIHR Moorfields Clinical Research Facility and Biomedical Research Centre, Moorfields Eye Hospital, London, UK.
Institute of Ophthalmology, University College London, London, UK.

Sarega Gurudas (S)

Institute of Ophthalmology, University College London, London, UK.

Wei-Shan Tsai (WS)

NIHR Moorfields Clinical Research Facility and Biomedical Research Centre, Moorfields Eye Hospital, London, UK.
Institute of Ophthalmology, University College London, London, UK.

Andrea Giani (A)

Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany.

Eduard De Cock (E)

Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany.

Taffeta Ching Ning Yamaguchi (TCN)

Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany.

Sobha Sivaprasad (S)

NIHR Moorfields Clinical Research Facility and Biomedical Research Centre, Moorfields Eye Hospital, London, UK. sobha.sivaprasad@NHS.net.
Institute of Ophthalmology, University College London, London, UK. sobha.sivaprasad@NHS.net.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH